Brokerages Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $9.25

Shares of Opus Genetics, Inc. (NASDAQ:IRD) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.3333.

Several analysts have commented on the stock. Wedbush raised their target price on shares of Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. upgraded shares of Opus Genetics to a “strong-buy” rating in a report on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a research report on Thursday, January 22nd. BTIG Research raised their price objective on shares of Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Lifesci Capital raised shares of Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th.

Opus Genetics News Roundup

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analyst support has been strengthening: Oppenheimer initiated coverage (outperform) and other firms (BTIG, Wedbush, Craig Hallum) have raised targets, lifting longer‑term upside expectations for IRD. Read More.
• Neutral Sentiment: Institutional buying and position changes were reported (several funds added or increased stakes), which may support demand over time but do not guarantee immediate price support. Read More.
• Neutral Sentiment: Technical/liquidity context: trading volume today is below average, the 50‑day and 200‑day moving averages are above the 200‑day, and the 12‑month range ($0.65–$5.30) frames near resistance — useful for timing trades but not a catalyst by itself. Read More.
• Negative Sentiment: Clustered insider selling on March 16 is a likely principal driver of the pullback: CEO George Magrath sold 24,438 shares (~$127k), COO Joseph Schachle and other executives sold several thousand shares each. These filings (Form 4s) signal modest reductions in insider stakes and likely put near‑term downward pressure on the stock. Read More. Read More.

Insider Transactions at Opus Genetics

In other news, CEO George Magrath sold 24,438 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.21, for a total value of $127,321.98. Following the sale, the chief executive officer directly owned 1,750,855 shares in the company, valued at $9,121,954.55. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cam Gallagher acquired 83,000 shares of Opus Genetics stock in a transaction dated Monday, December 29th. The shares were purchased at an average cost of $1.97 per share, with a total value of $163,510.00. Following the completion of the transaction, the director directly owned 83,000 shares of the company’s stock, valued at $163,510. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 34,692 shares of company stock valued at $180,672. Corporate insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

A number of large investors have recently bought and sold shares of the company. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics during the 4th quarter worth approximately $25,000. Comerica Bank bought a new stake in shares of Opus Genetics in the first quarter worth $29,000. Virtu Financial LLC acquired a new position in Opus Genetics during the fourth quarter worth $34,000. Raymond James Financial Inc. boosted its holdings in Opus Genetics by 95.6% during the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Johnson Investment Counsel Inc. bought a new position in Opus Genetics in the fourth quarter valued at $40,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Opus Genetics Price Performance

NASDAQ:IRD opened at $4.58 on Friday. The business’s 50-day simple moving average is $3.41 and its 200-day simple moving average is $2.42. Opus Genetics has a fifty-two week low of $0.65 and a fifty-two week high of $5.30. The stock has a market capitalization of $325.87 million, a PE ratio of -5.59 and a beta of 0.45.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.